138 related articles for article (PubMed ID: 26767545)
1. Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Sehra D; Sehra S
Recent Adv Cardiovasc Drug Discov; 2015; 10(1):4-9. PubMed ID: 26767545
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylureas: do we need to introspect safety again?
Sehra D; Sehra S; Sehra ST
Expert Opin Drug Saf; 2011 Nov; 10(6):851-61. PubMed ID: 21605015
[TBL] [Abstract][Full Text] [Related]
3. Sulfonylureas.
Zimmerman BR
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
[TBL] [Abstract][Full Text] [Related]
4. The second-generation sulfonylureas: change or progress?
Kreisberg RA
Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729
[No Abstract] [Full Text] [Related]
5. Are sulfonylureas passé?
Green JB; Feinglos MN
Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
[TBL] [Abstract][Full Text] [Related]
6. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
7. Effects of sulfonylureas on lipids in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Chen YH; Du L; Geng XY; Peng YL; Shen JN; Zhang YG; Liu GJ; Sun X
J Evid Based Med; 2015 Aug; 8(3):134-48. PubMed ID: 26066789
[TBL] [Abstract][Full Text] [Related]
8. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
Barry HC
Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
[No Abstract] [Full Text] [Related]
9. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
Del Prato S; Pulizzi N
Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
[TBL] [Abstract][Full Text] [Related]
10. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
Bell DS
Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
[TBL] [Abstract][Full Text] [Related]
11. Role of sulfonylureas in non-insulin-dependent diabetes mellitus: Part II--"The cons".
Heine RJ
Horm Metab Res; 1996 Sep; 28(9):522-6. PubMed ID: 8911991
[TBL] [Abstract][Full Text] [Related]
12. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
13. The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment.
Pan SW; Yen YF; Kou YR; Chuang PH; Su VY; Feng JY; Chan YJ; Su WJ
Chest; 2018 Jun; 153(6):1347-1357. PubMed ID: 29253553
[TBL] [Abstract][Full Text] [Related]
14. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
15. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
[No Abstract] [Full Text] [Related]
16. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
Rustenbeck I
Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
[TBL] [Abstract][Full Text] [Related]
17. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
[TBL] [Abstract][Full Text] [Related]
18. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
19. Is it time to ban sulfonylureas?
Ceriello A
J Diabetes; 2020 Nov; 12(11):848-850. PubMed ID: 32767650
[No Abstract] [Full Text] [Related]
20. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
